You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects

    SBC: General Biophysics LLC            Topic: NIA

    PHASE II APPLICATION(STTR Program PAS-22-197) “Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects” ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant role in the onset an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: PACDNA LLC            Topic: NCI

    Project Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeuticintervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a singlemutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitorshas heightened the importance of alternative methods targeting the o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia

    SBC: HOPEFUL AGING LLC            Topic: R

    PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, and Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly impact ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Field Instrument for Assessment of Arsenic Exposure

    SBC: GINER INC            Topic: R

    Project Summary Human exposure to toxic heavy metals existing in drinking water, food, and the environment is an area of increasing national and international concern. Heavy metals are significant environmental pollutants because they tend to persist, bioaccumulate and can result in serious adverse acute or chronic health effects after ingested or inhaled. Traditionally, trace metals are measured ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. New generation of catheters for treatment of atrial fibrillation

    SBC: LUXMED SYSTEMS INC            Topic: NHLBI

    ABSTRACT Atrial fibrillation (AF) remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality primarily due to poor hemodynamic performance and often stroke. One of the primary options to treat AF is cardiac ablation where the physician applies radiofrequency energy via percutaneous catheters to form a series of ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Point-of-care diagnostic test for T. cruzi (Chagas) infection

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Project Summary Chagas disease, caused by infection with the parasite Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infection is transmitted by an insect vector that is native to Latin America, but can also be acquired through blood transfusion, organ transplant, or congenitally. Follow ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Novel Bone Adhesive Scaffold to Accelerate Bone Regeneration and Improve Ridge Height Maintenance for the Treatment of Patients with Residual Ridge Resorption

    SBC: REVBIO, INC.            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACT Over 50% of US adults over the age of 45 have missing teeth. Following tooth loss, the alveolar portion of the jaw will atrophy in a process known as residual ridge resorption. While dental implant-supported crowns have become the standard of care, market research indicates that 70% of patients must undergo a ridge augmentation procedure to provide adequate bony structure ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer

    SBC: APREA THERAPEUTICS, INC.            Topic: 102

    PROJECT SUMMARY High-grade serous ovarian carcinoma (HGSOC) is a devastating disease responsible for the deaths of ~125,000 women worldwide each year. HGSOC has the lowest survival rates. More than 20% of HGSOCs harbor genetic mutations (e.g. BRCA1/2MUT) that cause defects in homologous recombination (HR), which causes sensitivity to PARPi. However, responses to PARPi are rarely durable and resist ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Colorimetric Sensor for Detection of Cerebrospinal Fluid Leaks

    SBC: DrinkSavvy, Inc.            Topic: 106

    PROJECT SUMMARY Chemeleon, Inc. is a NYC-based startup that is developing a novel colorimetric biosensor that rapidly diagnoses cerebrospinal fluid (CSF) leaks at the Point-of-Care (POC), such as by doctors to diagnose Traumatic Brain Injury (TBI) patients in the Emergency Department (ED), or the Emergency Medical Technician (EMT) in the ambulance, or during intraoperative and post-operative care ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government